Preclinical studies have demonstrated its effectiveness in both in vitro and in vivo settings, notably in BRAF inhibitor-resistant melanoma cell lines and xenografts, where it induced apoptosis more effectively than combined MEK/PI3K inhibition[115]. This evidence concerns the gene MAP2K7 and melanoma.